NGEN
NervGen Pharma Corp. (NASDAQ)
Healthcare — Biotechnology
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is headquartered in Vancouver, Canada.
Price History
Fundamentals
| Market Cap | $221.96M |
| P/E Ratio (TTM) | - |
| Forward P/E | -5.51 |
| EPS (TTM) | $-0.45 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -1207.46% |
| Debt/Equity | - |
| Recommendation | None |
| Analyst Target | $11.21 |
| Analysts | 6 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 65.8 |
| Beta | 0.69 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $6.30 |
| 52-Week Low | $1.70 |
| 50-Day Avg | $2.81 |
| 200-Day Avg | $3.57 |
| Avg Volume | 794.7K |
| Volume | 588.1K |
Performance Analysis
BULLISHNGEN shows predominantly bullish signals based on its fundamentals and technicals.
Recent News
Last updated: Jul 02, 2026 13:22 UTC
Back to Screener Export Report